Nicolson GL, Nass M, Nicolson N. 2000. Anthrax vaccine: controversy over safety and efficacy. Antimicrobics and Infectious Disease Newsletter 18:1–6.
Noah DN. 1997. Microbiology. In: Detels R, Holland WW, McEwen J, Omenn GS, eds. Oxford Textbook of Public Health. Vol. 2. The Methods of Public Health. 3rd ed. New York, N.Y.: Oxford University Press Inc. Pp. 929–949.
Ott G, Barchfeld GL, Chernoff D, Radhakrishmnan R, van Hoogevest P, Van Nest G. 1995. Design and evaluation of a safe and potent adjuvant for human vaccines. In: Powell MF, Newman MJ, Burdman JR, eds. Vaccine Design: The Subunit and Adjuvant Approach. New York, N.Y.: Plenum Press. Pp. 227–296.
Pittman PR, Kim-Ahn G, Pifat DY, Coon K, Gibbs P, Little S, Pace-Templeton J, Myers R, Parker GW, Friedlander AM. 2002. Anthrax vaccine: safety and immunogenicity of a dose-reduction, route comparison study in humans. Vaccine 20(9–10):1412–1420.
Rovet RJ, Lieutenant, U.S. Air Force. 1999. Anthrax Vaccine Adverse Event Reporting. Statement at the July 21, 1999, hearing of the Subcommittee on National Security, Veterans Affairs and International Relations, Committee on Government Reform, U.S. House of Representatives, Washington, D.C.
Ruben FL, Froeschle JE, Meschievitz C, Chen K, George J, Reeves-Hoche MK, Pietrobon P, Bybel M, Livingood WC, Woodhouse L. 2001. Choosing a route of administration for quadrivalent meningococcal polysaccharide vaccine: intramuscular versus subcutaneous. Clinical Infectious Diseases 32(1):170–172.
Rustgi VK, Schleupner CJ, Krause DS. 1995. Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2, and 12 months and Recombivax HB administered at 0, 1, and 6 months in healthy adults. Vaccine 13(17):1665–1668.
Scheifele DW, Bjornson G, Johnston J. 1990. Evaluation of adverse events after influenza vaccination in hospital personnel. Canadian Medical Association Journal 142(2):127–130.
Scheifele DW, Bjornson GJ. 1993. Evaluation of inactivated hepatitis A vaccine in Canadians 40 years of age or more. Canadian Medical Association Journal 148(4):551–555.
Schiff GM, Sherwood JR, Zeldis JB, Krause DS. 1995. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. Journal of Adolescent Health 16(1):12–17.
Selimov MA, Toigombaeva VS, Zgurskaya GN, Kulikova LG, Kodkind GK. 1988. Specific activity of tissue culture antirabic vaccine Rabivak-Vnukovo-32 with short intramuscular vaccination schedule. Acta Virologica 32(3):217–226.
Smith TJ. 2000. Squalene: potential chemopreventive agent. Expert Opinion on Investigational Drugs 9(8):1841–1848.
Strandberg TE, Tilvis RS, Miettinen TA. 1990. Metabolic variables of cholesterol during squalene feeding in humans: comparison with cholestyramine treatment. Journal of Lipid Research 31(9):1637–1643.
Treanor JJ. 2001. Adverse reactions following vaccination of adults. Commissioned paper. Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Institute of Medicine, Washington, D.C.
Tron F, Degos F, Brechot C, Courouce AM, Goudeau A, Marie FN, Adamowicz P, Saliou P, Laplanche A, Benhamou JP, et al. 1989. Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and PreS2 sequences. Journal of Infectious Diseases 160(2):199–204.
Van der Wielen M, Van Damme P, Joossens E, Francois G, Meurice F, Ramalho A. 2000. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine 18(20):2075–2082.